Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ArticleAbstract: Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovasculPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Colhoun H.M., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., DIaz R., Dilic M., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Loizeau V., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusPantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
ArticleAbstract: Background & Aims: Antiplatelets and anticoagulants are associated with increased upper gastrointestPalabras claves:drug, Heart Disease Prevention, Stomach, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Commerford P.J., Connolly S.J., Cook-Bruns N., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus